Replimune Group, Inc.(REPL)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

REPL iron condor setups REPL expected move REPL IV rank history REPL Fibonacci levels REPL insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

REPL $15.04 —
Snapshot
$15.04
52-Week Range
$1.50 – $16.33
YTD
+68.99%
IV Rank (30D)
5.71
Straddle Price
$2.28
P/C Vol Ratio
0.40
Market Cap
$1.4B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.79%
Beta vs SPY0.81
Cost of Equity (CAPM)8.84% (VRP-adj)
WACC9.03%
Volatility Risk Premium-153.2pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.3B
Return on Equity (TTM)-281.1%
Book / Price12.0%
Debt / Equity0.63
Quality Score0/6 — cyclical/struggling (5y DCF)
SMA 50$12.36 (Market Anchor value)
SMA 20 / Bollinger Mid$15.07
Bollinger Width / SMA20116.6% (drives anchor stability)
Net Debt$-0.1B
Market Cap$1B
Peers used for multiples: ABBV, AMGN, BMY, IONS, JNJ, LLY, PRAX, ROIV
Model Conviction
96%
20-Day Fair Value
≈ by Oct 6, 2026
$16.88
α +12.2% rank 73%
40-Day Fair Value
≈ by Nov 4, 2026
$18.24
α +21.3% rank 64%
60-Day Fair Value
≈ by Dec 3, 2026
$18.07
α +20.1% rank 34%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 31.9× · 5 peers
Peer EV/EBITDA n/a 0% median 17.8× · 5 peers
Peer P/B $14.25 21% median 7.9× · 7 peers
Peer P/S n/a 0% median 7.1× · 7 peers
Market Anchor (SMA50) $12.36 79% stability 74% (BB-width)
Options Expected (B-L 30d) $7.39 0% 5 strikes · skew +0.33
As of 2026-09-07 · updated
Info
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
Exchange
XNAS
Market Cap
$1.4B

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death …

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -1.85% 8
Feb -5.36% 8
Mar -9.05% 8
Apr +2.55% 8
May +25.71% 8
Jun +21.43% 8
Jul -6.82% 9
Aug +6.42% 9
Sep -5.22% 9
Oct +26.81% 8
Nov +3.42% 8
Dec -9.08% 8
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $15.07
SMA 50: $12.36
SMA 200: $8.61
Current: $15.04
EMA 12: $15.18
EMA 26: $14.18
MACD: 1.0016 | Signal: -0.1591
BULLISH
ADX (14): 31.02
TREND
+DI: 29.77
−DI: 19.12

Momentum Oscillators

RSI (14): 56.63
NEUTRAL
Stoch %K: 64.55
Stoch %D: 72.22
Williams %R: -51.19

Volume & Volatility

BB Upper: $16.39
BB Lower: $13.74
NEUTRAL
OBV: 330,717,782
Vol SMA 20: 3,177,584
Vol ROC: -69.42%
ATR: $1.06
True Range: $0.53
HV 20: 78.8%
HV 30: 269.8%
HV 60: 196.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-06T00:00:00 – 2026-09-04T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

BULLISH (Confidence Level: 7/10)

Key Drivers:

  • Technical indicators suggest a bullish trend, with MACD and RSI indicating momentum
  • Recent news headlines highlight positive sentiment, particularly the FDA advisory committee meeting outcome

Primary Risks:

  • High volatility, reflected in beta value of 1.34
  • Negative news headlines about class-action lawsuits may impact investor confidence

Investment Thesis:

REPL is a high-growth biotech stock with significant potential for upside, driven by its innovative cancer treatment approach and recent FDA advisory committee meeting outcome. However, investors should be aware of the company's exposure to class-action lawsuits and potential volatility.

Recent News Sentiment Impact:

The positive news headlines about the FDA advisory committee meeting outcome have contributed to the bullish sentiment, while negative headlines about class-action lawsuits may weigh on investor confidence.

Technical Analysis

Trend Direction:

  • Short-term: Bullish (upward momentum)
  • Medium-term: Bullish (MACD and RSI indicate momentum)
  • Long-term: Neutral (no clear direction)

Support/Resistance Levels:

  • SMA 20: $15.07
  • Upper Bollinger Band: $16.39

Momentum Signals:

  • MACD signal line is above the zero line, indicating bullish momentum
  • RSI is neutral at 56.63%, suggesting no overbought or oversold conditions
  • Williams %R is -51.19%, indicating oversold conditions (potential buy signal)

Volume Analysis:

  • Volume SMA 20: 3177584.91
  • On-Balance Volume (OBV): 330717782.72
  • Volume Rate of Change: -69.42% (indicating reduced trading activity)

News & Sentiment Analysis

Recent Headlines Summary:

  • Positive news headlines about FDA advisory committee meeting outcome and company's innovative approach to cancer treatment
  • Negative news headlines about class-action lawsuits and potential legal issues

Sentiment Assessment:

  • Aggregate sentiment is NEUTRAL, with a slight BULLISH bias due to recent positive news headlines

Catalyst Identification:

  • Upcoming earnings report (no specific date available)
  • Regulatory approvals or setbacks for RP1 in advanced melanoma treatment

Market Narrative:

The technical indicators and recent news headlines suggest a bullish trend, while the negative news about class-action lawsuits may weigh on investor confidence. The market narrative is NEUTRAL to BULLISH.

Risk & Volatility Assessment

Beta Interpretation:

  • Beta value of 1.34 indicates high volatility relative to the market

Volatility Regime:

  • Current volatility level is HIGH compared to historical averages

Options Market Signals:

  • IV rank: 5.7% (Low - shows if volatility is historically high/low)
  • Put/call volume ratio: 0.40 (Bullish sentiment)

Downside Protection:

  • Support levels at SMA 20 and Bollinger Band middle line
  • Risk management considerations include stop-loss levels and position sizing

Market Context & Positioning

Sector Performance:

  • Relative strength vs sector/market is NEUTRAL to BULLISH

Institutional Activity:

  • Volume patterns suggest institutional interest in the stock

Correlation Analysis:

  • Correlation with SPY is 0.08, indicating low correlation

Relative Valuation:

  • Position within trading range is NEUTRAL to BULLISH

Key Levels & Action Items

Critical Price Levels:

  • SMA 20: $15.07
  • Upper Bollinger Band: $16.39

Breakout/Breakdown Levels:

  • None identified based on technical indicators and recent price action

Time-Sensitive Catalysts:

  • Upcoming earnings report (no specific date available)
  • Regulatory approvals or setbacks for RP1 in advanced melanoma treatment

Risk Management:

  • Stop-loss levels at SMA 20 and Bollinger Band middle line
  • Position sizing considerations include reducing exposure to minimize potential losses
Generated
Earnings History
7 of 7 under expected move
Avg Expected Move
11.63%
Avg Actual Move
2.55%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-11-12 Pre-Market 8.20% 2.48% 0.30x Within
2025-02-12 After-Close 16.33% 0.41% 0.03x Within
2025-05-22 Pre-Market 28.99% 3.67% 0.13x Within
2025-08-07 After-Close 5.98% 2.59% 0.43x Within
2025-11-06 Pre-Market 8.12% 2.29% 0.28x Within
2026-02-03 After-Close 9.88% 5.47% 0.55x Within
2026-07-02 After-Close 3.89% 0.95% 0.24x Within
Options Activity
IV Rank (30D)
5.71
IV Rank (7D)
73.72
Avg IV
116.6%
Straddle (30D)
$2.28
Straddle (7D)
$0.95
P/C Volume
0.40
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
1.34
Correlation (SPY)
7.8%
R²
0.01
Ann. Volatility
217.6%
SPY Volatility
12.7%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 92,105,815 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

203 filers98,720,014 shares$1.07B value107.18% of float
# Filer Shares Value % of Total % of Float Period
1 BAKER BROS. ADVISORS LP 11,045,336 $122.27M 11.46% 11.99% 2026-06-30
2 BlackRock, Inc. Custodian 8,958,535 $99.17M 9.30% 9.73% 2026-06-30
3 RTW INVESTMENTS, LP 7,411,581 $82.05M 7.69% 8.05% 2026-06-30
4 Ridgeback Capital Investments L.P. 7,310,656 $80.93M 7.59% 7.94% 2026-06-30
5 GOLDMAN SACHS GROUP INC Custodian 4,541,018 $50.27M 4.71% 4.93% 2026-06-30
6 STATE STREET CORP 4,440,144 $49.15M 4.61% 4.82% 2026-06-30
7 MONTANOVA CAPITAL, LLC 4,389,836 $48.60M 4.56% 4.77% 2026-06-30
8 Boxer Capital Management, LLC 3,983,000 $44.09M 4.13% 4.32% 2026-06-30
9 VANGUARD GROUP INC Custodian 3,776,198 $36.70M 3.44% 4.10% 2025-12-31
10 VANGUARD CAPITAL MANAGEMENT LLC 2,896,004 $32.06M 3.01% 3.14% 2026-06-30
11 FCPM III SERVICES B.V. 2,808,368 $31.09M 2.91% 3.05% 2026-06-30
12 AQR CAPITAL MANAGEMENT LLC Custodian 2,566,241 $28.41M 2.66% 2.79% 2026-06-30
13 Logos Global Management LP 2,500,000 $27.68M 2.59% 2.71% 2026-06-30
14 JANE STREET GROUP, LLC Custodian 2,322,545 $25.71M 2.41% 2.52% 2026-06-30
15 Erste Asset Management GmbH 2,120,000 $23.74M 2.23% 2.30% 2026-06-30
16 GEODE CAPITAL MANAGEMENT, LLC Custodian 2,035,187 $22.53M 2.11% 2.21% 2026-06-30
17 D. E. Shaw & Co., Inc. Custodian 1,789,964 $19.81M 1.86% 1.94% 2026-06-30
18 Opaleye Management Inc. 1,384,993 $15.33M 1.44% 1.50% 2026-06-30
19 TORONTO DOMINION BANK 1,275,000 $14.11M 1.32% 1.38% 2026-06-30
20 UBS Group AG Custodian 1,128,276 $12.49M 1.17% 1.23% 2026-06-30
21 Artisan Partners Limited Partnership 973,496 $10.78M 1.01% 1.06% 2026-06-30
22 FMR LLC Custodian 929,375 $10.29M 0.96% 1.01% 2026-06-30
23 MILLENNIUM MANAGEMENT LLC Custodian 821,958 $9.10M 0.85% 0.89% 2026-06-30
24 CITADEL ADVISORS LLC Custodian 784,233 $8.68M 0.81% 0.85% 2026-06-30
25 Caption Management, LLC 783,873 $8.68M 0.81% 0.85% 2026-06-30
16 filers$72.76M notional
# Filer Notional Value % of Total Period
1 Caption Management, LLC $32.69M 44.93% 2026-06-30
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $12.22M 16.79% 2026-06-30
3 DIADEMA PARTNERS LP $7.71M 10.59% 2026-06-30
4 CITADEL ADVISORS LLC Custodian $7.50M 10.31% 2026-06-30
5 BARCLAYS PLC Custodian $3.50M 4.81% 2026-06-30
6 SIMPLEX TRADING, LLC Custodian $3.41M 4.68% 2026-06-30
7 GROUP ONE TRADING LLC Custodian $3.04M 4.17% 2026-06-30
8 JANE STREET GROUP, LLC Custodian $1.50M 2.07% 2026-06-30
9 Persistent Asset Partners Ltd $396.97K 0.55% 2026-06-30
10 Walleye Capital LLC $228.04K 0.31% 2026-06-30
11 PEAK6 LLC $221.40K 0.30% 2026-06-30
12 GOLDMAN SACHS GROUP INC Custodian $110.70K 0.15% 2026-06-30
13 Walleye Trading LLC $109.59K 0.15% 2026-06-30
14 WOLVERINE TRADING, LLC Custodian $75.08K 0.10% 2025-09-30
15 HAP TRADING, LLC $61.60K 0.08% 2025-09-30
16 INGALLS & SNYDER LLC $111 <0.01% 2026-06-30
18 filers$35.07M notional
# Filer Notional Value % of Total Period
1 DIADEMA PARTNERS LP $5.56M 15.86% 2026-06-30
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $5.33M 15.20% 2026-06-30
3 CITADEL ADVISORS LLC Custodian $5.16M 14.72% 2026-06-30
4 SIMPLEX TRADING, LLC Custodian $3.83M 10.92% 2026-06-30
5 CITIGROUP INC Custodian $3.32M 9.47% 2026-06-30
6 Caption Management, LLC $2.45M 6.98% 2026-06-30
7 GROUP ONE TRADING LLC Custodian $2.35M 6.69% 2026-06-30
8 D. E. Shaw & Co., Inc. Custodian $2.21M 6.31% 2026-06-30
9 MILLENNIUM MANAGEMENT LLC Custodian $1.87M 5.32% 2026-06-30
10 JANE STREET GROUP, LLC Custodian $1.37M 3.90% 2026-06-30
11 DLD Asset Management, LP $553.00K 1.58% 2026-06-30
12 Verition Fund Management LLC $442.80K 1.26% 2026-06-30
13 TUDOR INVESTMENT CORP ET AL $219.19K 0.62% 2026-06-30
14 Walleye Trading LLC $212.54K 0.61% 2026-06-30
15 Persistent Asset Partners Ltd $115.20K 0.33% 2026-06-30
16 WOLVERINE TRADING, LLC Custodian $60.76K 0.17% 2025-09-30
17 Walleye Capital LLC $11.07K 0.03% 2026-06-30
18 HAP TRADING, LLC $10.00K 0.03% 2025-09-30
Insider Activity
Latest: 2026-08-24
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-24 Philip Astley-Sparke Director Gift (G) −50,000 — EDGAR
2026-08-19 Emily Luisa Hill Chief Financial Officer Sell (S) −9,256 $14.28 -$132.2K EDGAR
2026-08-12 Andrew Schwendenman Chief Accounting Officer Sell (S) −7,632 $12.97 -$99.0K EDGAR
2026-08-12 Emily Luisa Hill Chief Financial Officer Sell (S) −11,448 $12.97 -$148.5K EDGAR
2026-08-12 Konstantinos Xynos Chief Medical Officer Sell (S) −11,447 $12.97 -$148.5K EDGAR
2026-08-12 Sushil Patel Chief Executive Officer Sell (S) −39,341 $12.97 -$510.3K EDGAR
2026-08-11 JULIAN BAKER Director Buy (P) +16,418,040 RSU — EDGAR
2026-06-03 Christopher Sarchi Chief Commercial Officer Sell (S) −12,000 $9.24 -$110.9K EDGAR
2026-05-20 Andrew Schwendenman Chief Accounting Officer Sell (S) −7,894 $5.08 -$40.1K EDGAR
2026-05-20 Sushil Patel Chief Executive Officer Sell (S) −37,324 $5.08 -$189.6K EDGAR
2026-05-20 Emily Luisa Hill Chief Financial Officer Sell (S) −7,812 $5.08 -$39.7K EDGAR
2026-05-20 Christopher Sarchi Chief Commercial Officer Sell (S) −8,626 $5.08 -$43.8K EDGAR
2026-05-20 Konstantinos Xynos Chief Medical Officer Sell (S) −14,023 $5.08 -$71.2K EDGAR
2026-05-20 Philip Astley-Sparke Director Sell (S) −17,657 $5.08 -$89.7K EDGAR
2026-04-07 Christopher Sarchi Chief Commercial Officer Award (A) +50,000 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
26 insiders · @ $15.04
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Omega Fund IV G.P. Manager, Ltd. 10%+ Owner 9,475,522 $142.51M -$5.98M 7 2022-03-16
2 Omega Fund IV GP, L.P. Director 4,853,705 $73.00M $5.82M 5 2021-11-10
3 Omega Fund IV, L.P. Director 4,811,398 $72.36M -$9.86M 4 2021-11-16
4 Otello Stampacchia Director 4,811,245 $72.36M -$5.86M 2 2021-11-18
5 Hugo Alexander Slootweg Director 4,588,116 $69.01M $2.00M 6 2023-04-04
6 ATLAS VENTURE ASSOCIATES X, L.P. 10%+ Owner 4,453,386 $66.98M $0 1 2018-07-26
7 Atlas Venture Fund X, L.P. 10%+ Owner 2,486,296 $37.39M $0 4 2020-09-17
8 Jeffrey Lawrence Schwartz 10%+ Owner 2,338,968 $35.18M $45.00M 1 2018-07-26
9 Robert Coffin President & Chief R&D Officer 1,821,872 $27.40M -$21.06M 20 2024-05-20
10 Philip Astley-Sparke Director 1,362,414 $20.49M -$6.90M 21 2026-08-24
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-04-02
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-04-02 Christopher Sarchi Officer 18,500 $142.4K 2026-04-02 J.P. Morgan Securities LLC 10b5-1 EDGAR
2025-12-09 Kapil Dhingra Director 3,164 $32.8K 2025-12-09 J.P. Morgan Securities LLC — EDGAR
2025-12-02 Sushil Patel Chief Strategy Officer 10,000 $111.3K 2025-12-02 J.P. Morgan Securities LLC 10b5-1 EDGAR
2024-12-16 Sushil Patel Chief Strategy Officer 15,000 $188.6K 2024-12-16 J.P. Morgan Securities LLC 10b5-1 EDGAR
2024-06-07 Konstantinos Xynos Officer 15,881 $119.2K 2024-06-07 J.P. Morgan Securities LLC 10b5-1 EDGAR
2024-05-23 Pamela Esposito Officer 79,710 $472.7K 2024-05-23 J.P. Morgan Securities LLC 10b5-1 EDGAR
2023-07-10 Pamela Esposito Officer 80,000 $1.69M 2023-07-10 J.P. Morgan Securities LLC 10b5-1 EDGAR
2023-06-13 Tanya Lewis Affiliate 22,486 $527.3K 2023-06-13 J.P. Morgan Securities LLC 10b5-1 EDGAR
2023-06-13 Sushil Patel Affiliate 23,710 $556.0K 2023-06-13 J.P. Morgan Securities LLC 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio13.6
EV/EBITDA-4.6
TTM Net Income$-0.3B
TTM EPS$-3.38
ROE-281.1%
Debt/Equity1.03